Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» August 2011
August 2011
1-Star Stocks Poised to Plunge: Pharmasset?
1-Star Stocks Poised to Plunge: Pharmasset?
Motley Fool
Pharmasset
Analyst Says Xarelto Niche "Still Secure"
Analyst Says Xarelto Niche "Still Secure"
Forbes
Xarelto
bloodthinners
Bayer
JNJ
Pfizer
Bristol-Myers Squibb
Eliquis
Pfizer, Bristol-Myers May Lead $9B Stroke Market
Pfizer, Bristol-Myers May Lead $9B Stroke Market
Bloomberg
stroke
bloodthinners
Pfizer
Eliquis
Bristol-Myers Squibb
Ahead of the Bell: Analyst sees Pfizer drug growth
Ahead of the Bell: Analyst sees Pfizer drug growth
Yahoo/AP
Pfizer
Xalkori
lung cancer
Abbott Laboratories
Vinita Gupta's entrepreneurial drive: Lupin now a big pharma player in the US
Vinita Gupta's entrepreneurial drive: Lupin now a big pharma player in the US
The Economic Times, India
Lupin
Is Amgen's Stock a Bargain?
Is Amgen's Stock a Bargain?
Motley Fool
Amgen
Aspirin, Cheap Drugs Not Used Enough to Treat Heart Disease
Aspirin, Cheap Drugs Not Used Enough to Treat Heart Disease
Bloomberg
heart disease
aspirin
statins
beta blockers
ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial
ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial
Yahoo/BusinessWire
Eliquis
Apixaban
Warfarin
atrial fibrillation
stroke
Bristol-Myers Squibb
Pfizer
ARISTOTLE trial
Add Questcor To Your Diversified High-Growth Biotech Portfolio
Add Questcor To Your Diversified High-Growth Biotech Portfolio
Seeking Alpha
Questcor Pharmaceuticals
Human Genome Sciences: Slow Benlysta Launch Results In Good Short Candidate
Human Genome Sciences: Slow Benlysta Launch Results In Good Short Candidate
Seeking Alpha
Benlysta
Human Genome Sciences
lupus
GSK
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »